Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Expects Sales Loss To Be Skin-Deep, Looks To Skin-Care Lines For Boost

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson looks to rebound from its first yearly decline in sales since the Depression in part by capitalizing on momentum in its skin-care business with extensions of its Aveeno, Neutrogena and RoC lines designed to meet anti-aging needs around the clock

You may also be interested in...

McNeil Expands Tylenol Recall As FDA Criticizes Firm's Response To AERs

McNeil Consumer Healthcare's reaction to signs of potentially contaminated packaging for OTC products including Tylenol raised FDA's ire and is now costing the firm an extensive product recall

J&J Ready To Capitalize On Zyrtec OTC Launch As Allergy Drug Hits Shelves

Johnson & Johnson's consumer product business is positioned to capitalize on the launch of nonprescription Zyrtec (cetirizine HCl) allergy medicine, J&J CEO Bill Weldon said during the firm's year-end analyst meeting Jan. 22

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts